



Correction to: PET imaging of sympathetic innervation with [^{18}F]Flubrobenguane vs [^{11}C]mHED in a patient with ischemic cardiomyopathy

Jason G. E. Zelt, MSc,^{a,b} Lisa M. Mielniczuk, MSc, MD,^{a,b} Cesare Orlandi, MD,^c Simon Robinson, PhD,^c Tayebah Hadizad, PhD,^a Olga Walter, RN,^a Linda Garrard, RN,^a Rob S. B. Beanlands, MD,^{a,b} and Robert A. deKemp, PhD^a

^a Division of Cardiology, Department of Medicine, Molecular Function and Imaging Program, The National Cardiac PET Centre, University of Ottawa Heart Institute and University of Ottawa, Ottawa, ON, Canada

^b Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

^c Lantheus Medical Imaging, North Billerica, MA

doi:10.1007/s12350-019-02018-x

CORRECTION TO:

J NUCL CARDIOL (2019) 26:2151–3

<https://doi.org/10.1007/s12350-018-01527-5>

At time of initial publication, the USAN Council had assigned the generic name for LMI1195 as Flurobenguan. However, the Council has since changed

and finalized this compound name as Flubrobenguane which is recommended as the generic name to be used in the future.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12350-018-01527-5>.

Reprint requests: Robert A. deKemp, PhD, Division of Cardiology, Department of Medicine, Molecular Function and Imaging Program, The National Cardiac PET Centre, University of Ottawa Heart Institute and University of Ottawa, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada; RAdeKemp@ottawaheart.ca

J Nucl Cardiol 2020;27:702.

1071-3581/\$34.00

Copyright © 2020 American Society of Nuclear Cardiology.